Physician profile
Gary J Collins
NPI 1558319962
$8,106.23
in general payments reported to CMS, 2019-2025
31 companies · $24.37 in 2025
The $24.37 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,741 · 2020: $1,020 · 2021: $1,276 · 2022: $973 · 2024: $72.26 · 2025: $24.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $96.63.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $96.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,876.14 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $1,038.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $934.58 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $739.00 | 2019-2022 | |
| Amgen INC. | $631.60 | 2019-2022 | |
| Abiomed | $564.75 | 2019-2021 | |
| Boston Scientific Corporation | $492.97 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $239.75 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $209.19 | 2019-2021 | |
| Abbott Laboratories | $201.71 | 2019-2025 | Cardiomems |
| Sanofi-Aventis U.S. LLC | $143.93 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $133.28 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $118.34 | 2019-2021 | |
| Astellas Pharma US INC | $103.78 | 2019-2020 | |
| Amarin Pharma, INC. | $102.72 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $96.47 | 2019-2022 | |
| Philips North America LLC | $81.68 | 2020-2022 | |
| Asahi Intecc USA, INC. | $75.73 | 2022 | |
| Portola Pharmaceuticals, LLC | $62.36 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $55.26 | 2019-2022 | |
| Lundbeck LLC | $52.72 | 2019-2020 | |
| Cardiva Medical, INC. | $27.33 | 2024 | Cardiva Vascade Mvp Vvcs 6-12f |
| Akcea Therapeutics, INC. | $17.90 | 2020 | |
| Biotronik INC. | $17.70 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.80 | 2020 | |
| Esperion Therapeutics, INC. | $14.34 | 2020 | |
| Cardiovascular Systems INC. | $14.26 | 2020 | |
| Irhythm Technologies, INC. | $14.11 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Gilead Sciences, INC. | $11.37 | 2019 | |
| Bardy Diagnostics, INC. | $6.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.